Loading clinical trials...

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials | Clinical Trials | Clareo Health

RECRUITING

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

A Retrospective, Multicountry Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318•Janssen-Cilag Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to describe the use of teclistamab/talquetamab in the treatment of patients with RRMM outside of clinical trials.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a documented diagnosis of multiple myeloma
•Received the first dose of teclistamab on or before 31 December 2022, regardless of the duration of teclistamab treatment (REALiTEC cohort 1) OR Received the first dose of teclistamab from 01 January 2023 to 31 December 2024, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 2) OR Received the first dose of teclistamab from 01 January 2025 to 31 December 2025, inclusive, regardless of the duration of teclistamab treatment (REALiTEC cohort 3) OR Received the first dose of talquetamab on or before 31 December 2023, regardless of the duration of talquetamab treatment (REALiTAL cohort). Participants who received both teclistamab \& talquetamab can be included in both REALiTEC and REALiTAL cohorts
•Received at least one dose of teclistamab/talquetamab
•Provision of a patient-signed informed consent form (ICF), or an ICF waiver for deceased patients as applicable based on country/site-specific requirements

Exclusion Criteria

•To be excluded from REALiTEC cohorts if received teclistamab as part of an interventional clinical trial
•To be excluded from REALiTAL cohort if received talquetamab as part of an interventional clinical trial
•Participants who have received teclistamab as part of a Janssen pre-approval access program are excluded from the REALiTEC Cohort 2 and REALiTEC Cohort 3

Locations (68)

Aalborg Sygehus Syd

Aalborg, Denmark

Aarhus Universitetshospital

Aarhus N, Denmark

Rigshospitalet

Copenhagen, Denmark

Odense University Hospital

Odense, Denmark

Sygehus Lillebælt, Vejle

Vejle, Denmark

Hopital Albert Calmette - CHU Lille

Lille, France

Institut Paoli Calmettes

Marseille, France

CHU de Nantes hotel Dieu

Nantes, France

Hopital Saint Louis

Paris, France

Institut Universitaire du Cancer Toulouse Oncopole

Toulouse, France

Key Dates

Start Date

December 18, 2023

Primary Completion Date

June 30, 2026

Completion Date

July 31, 2026

Last Updated

March 12, 2026

Enrollment

900

ESTIMATED participants

Conditions

Relapsed/Refractory Multiple Myeloma (RRMM)

Interventions

Teclistamab

OTHER

Talquetamab

OTHER

Contacts

Study Contact

CONTACT

844-434-4210 Participate-In-This-Study1@its.jnj.com